No. As of September 2026, Invivyd, Inc. (IVVD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 52.3% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 52.3% / 33% · Receivables / Mkt Cap (36m) 5.05% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 52.3% / 33.33% · Receivables / Mkt Cap (24m) 5.05% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 75.7% / 33.33% · Receivables / Avg Assets (4Q) 5.45% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 68.7% / 33.33% · (Cash+Recv) / Total Assets 75.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Invivyd, Inc. (IVVD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Invivyd, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Invivyd, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Invivyd, Inc. (NASDAQ: IVVD) is a Healthcare company (Biotechnology) with a market capitalization of $151M. The Maz Rating grades it against the other companies in its sector.
Invivyd, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.51, Invivyd, Inc. trades at 2.6x sales and 1.2x book value. Over the last twelve months it generated about $58M of revenue and a net loss of $122M. It runs a gross margin of 91.8%, an operating margin of -224.4% and a net margin of -214.8%. It shows return on equity of -67.2%, return on invested capital of -85.8% and a free cash flow yield of -84.6%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 5.51. Over the past 52 weeks the share price ranged from $0.49 to $3.01, with a beta of 0.71.
Invivyd, Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 5 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Invivyd, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Invivyd maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.